Introduction to Computer System Validation
Transcript of Introduction to Computer System Validation
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
1
Introduction to Computer System Validation
CS101: Building Your Essential Skill Set
V 18.01
• Instructor Introduction– Rodrigo Perez - [email protected]
• Student Introductions– Name
– Industry (e.g., pharmaceutical, medical device, clinical trials)
– Organization (e.g., IT, QA, Audit)
– How do you intend to apply the knowledge from this course (e.g., new system project, retrospective validation)
– Is there one thing you would like to know by tomorrow that you don’t know now…
Introductions
Validation Center™ Copyright © 2021, ProPharma Group 2
1
2
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
2
• At the conclusion of this course, you will:– Understand the background of computer system validation (CSV) requirements
– Be able to describe the framework and deliverables of CSV
– Be able to discuss the principles of testing and the associated documentation that the FDA expects
– Demonstrate basic knowledge of 21 CFR Part 11 (electronic records and electronic signatures) applicability and requirements
Course Objectives
Validation Center™ Copyright © 2021, ProPharma Group 3
Agenda
Validation Center™ Copyright © 2021, ProPharma Group 4
Part 1 Introduction FDA Introduction
BREAK (20 minutes)
21 CFR 11 and Annex 11 CSV Framework, Deliverables,
& Plan
Homework: FDA Guidance Documents
Part 2 Review Homework Requirements and Design
BREAK (20 minutes)
Validation Testing Final Exam (30 minutes) Review Exam Answers Wrap up
Introduction 21 CFR 11 and Annex 11
Framework, Deliverables,
& Plan
Requirements & Design
Validation Testing Evaluation
3
4
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
3
• Presentation and Discussion
• Class resource web page– https://validationcenter.com/icsv-resources/
– Password: _____
• Student Worksheet – Notes, Classroom questions, Homework questions
• Final Exam (open book)
Class Format
Validation Center™ Copyright © 2021, ProPharma Group 5
FDA Definition
Validation Center™ Copyright © 2021, ProPharma Group 6
The FDA defines software validation as…
Source: General Principles of Software Validation: Final Guidance for Industry and FDA Staff
Confirmation by examination and provision of objective evidence that software specifications conform to user needs and intended uses, and
that the particular requirementsimplemented through software can be
consistently fulfilled
The examination needs to confirm that the software will work in all anticipated
situations
Examine the software to
confirm that it functions as
defined in the requirements and that it will
be suitable for the
intended use
Document all validation
activities and test results
Define what the user
needs to do with the software and how
they will use the software
Define how the software
needs to work to enable the intended use
5
6
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
4
CSV Purpose and Benefits
Validation Center™ Copyright © 2021, ProPharma Group 7
Safety
Effectiveness
AccuracyIntegrity
FDA Introduction
Module 1
7
8
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
5
1. High-level FDA history
2. Key regulations impacting computer system validation
Learning Objectives
Validation Center™ Copyright © 2021, ProPharma Group 9
FDA Regulations 21 CFR Part 11
Framework & Deliverables
Requirements & Design
Validation Testing Evaluation
• The evolution of regulatory legislation – Tragedies have tended to drive the regulatory process.
• It has grown over the years to include more and more areas– Design, manufacturing, packaging, labeling, testing, and even to the realm of
computer software which supports these areas.
• It helps to understand the context of FDA, the mindset of the agency and its auditors.
– Part of the government
– Value of a single life
– With free press that drives public opinion
– In a democracy (elected officials)
Introduction to the FDA
Validation Center™ Copyright © 2021, ProPharma Group 10
9
10
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
6
The Food and Drug Administration
Validation Center™ Copyright © 2021, ProPharma Group 11
•FDA's mission is to promote and protect the public health.
• Its work is a blending of law and science aimed at protecting consumers.
• FDA has chemists, microbiologists, physicians, pharmacologists, and other
scientists, as well as investigators and inspectors who conduct more than 15,000
inspections a year.
• FDA has over 11,000
employees, located in 223
U.S. cities, China, India,
Mexico, Costa Rica, Chile,
Belgium, & the U.K.
• The mission of the FDA reflects and underscores Quality
• Enforcement– FDA acts as a law enforcement agency
– In Fiscal Year 2011, the efforts of FDA’s Office of Criminal Investigations (OCI) resulted in 255 convictions and $4.2 Billion in fines and restitutions
• Inspections can occur for several reasons– Routine GMP inspection (every 2 – 3 years)
– Routine Bioresearch Monitoring (GCP) inspection
– Pre-approval request (for example, for a new product, process change)
– FDA concern (for example, after a complaint or recall)
What It’s All About
Validation Center™ Copyright © 2021, ProPharma Group 12
11
12
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
7
Regulatory Compliance
Validation Center™ Copyright © 2021, ProPharma Group 13
• Lists inspection observations that are potential violationsForm FDA-483
• If FDA is not satisfied with a 483 responseWarning Letter
• Very serious – may last for yearsConsent Decree
Understand the FDA mindset: “If it isn’t documented, it didn’t happen”
• The FDA’s regulations are contained in Title 21 of the Code of Federal Regulations
– The Code of Federal Regulations (CFR)
– Title 21 of the CFR (21 CFR)
• CFR Title 21 database (searchable):– http://www.fda.gov Click Code of Federal Regulations
FDA’s Federal Regulations
Validation Center™ Copyright © 2021, ProPharma Group 14
13
14
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
8
CFR Title 21
Validation Center™ Copyright © 2021, ProPharma Group 15
CFR Title 21 contains many diverse Parts• Part 7: FDA Enforcement policy• Part 11: Electronic Records, Electronic Signatures• Part 21: Protection of Privacy• Part 50: Protection of human subjects• Part 70: Color Additives• Part 107: Infant Formula• Part 135: Frozen Desserts• Part 161: Fish and Shellfish• Part 216: Pharmacy Compounding• Part 316: Orphan Drugs• Part 501: Animal Food Labeling• Part 515: Medicated Feed Mill License• Part 701: Cosmetic Labeling• Part 1140: Cigarettes and Smokeless Tobacco• Part 1250: Interstate Conveyance Sanitation
Examples
CFR Title 21: Key Parts for Systems
Validation Center™ Copyright © 2021, ProPharma Group 16
Topic Part TitleElectronic Records
& Signatures 21 CFR 11 Electronic Records; Electronic Signatures
Clinical Trials 21 CFR 50 Protection of Human Subjects
Clinical Trials 21 CFR 56 Institutional Review Boards
Nonclinical Lab Studies
21 CFR 58 Good Laboratory Practice for Nonclinical Laboratory Studies
Infant Formula 21 CFR 106 Infant Formula Requirements Pertaining to Good Manufacturing Practice, Quality Control Procedures, Quality Practices, Records and Reports, and Notifications
Drugs 21 CFR 210 Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs; General
Finished Pharmaceuticals
21 CFR 211 Current Good Manufacturing Practice for Finished Pharmaceuticals
Drugs 21 CFR 312 Investigational New Drug Application
Drugs 21 CFR 314 Application for FDA Approval to Market a New Drug
Biological Products 21 CFR 600 Biological Products: General
Blood & Components
21 CFR 606 Current Good Manufacturing Practice for Blood and Blood Components
Medical Devices 21 CFR 803 Medical Device Reporting
Medical Devices 21 CFR 806 Medical Devices: Reports of Corrections and Removals
Medical Devices 21 CFR 820 Quality System Regulation (Medical Device GMP)
Cells and Tissue Products 21 CFR 1271 Human Cells, Tissues, and Cellular and Tissue-Based Products
15
16
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
9
• Very few regulations specifically deal directly with computers or automated systems
• There is no specific regulation that defines How To perform computer system validation
• Validation of computer or other automated systems are governed by the “predicate rules” or regulations
What About Computer Systems?
Validation Center™ Copyright © 2021, ProPharma Group 17
Predicate Rules vs. Part 11
Validation Center™ Copyright © 2021, ProPharma Group 18
21 CFR 820Quality System Regulation
(Medical Device GMP)
21 CFR 211Current Good Manufacturing Practice
for Finished Pharmaceuticals
21 CFR 58Good Laboratory Practice for
Nonclinical Laboratory Studies
21 CFR 600Biological Products: General
21 CFR 606Current Good Manufacturing Practice
for Blood and Blood Components
21 CFR 50Protection of Human Subjects
Predicate Rules, examples
Predicate Rules contain product-specific requirements(whether paper/manual or electronic/automated)
• Processes and business rules• Data transmissions to FDA
• Records and data• Record retention time
21 CFR 106Infant Formula … GMP, QC
Procedures, … Records and Reports
21 CFR 1271cGMP for Human Cells, Tissues, and Cellular and Tissue-Based Products
17
18
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
10
Predicate Rule Examples
Validation Center™ Copyright © 2021, ProPharma Group19
21 CFR 211.150 Distribution procedures. Written procedures shall be established, and followed, describing the distribution of drug products. They shall include:
(a) A procedure whereby the oldest approved stock of a drug product is distributed first. Deviation from this requirement is permitted if such deviation is temporary and appropriate.
(b) A system by which the distribution of each lot of drug product can be readily determined to facilitate its recall if necessary.
Predicate Rule Examples
Validation Center™ Copyright © 2021, ProPharma Group20
Subpart J--Records and Reports 21 CFR Part 211.196 Distribution Records
Distribution records shall contain the name and strength of the product and description of the dosage form, name and address of the consignee, date and quantity shipped, and lot or control number of the drug product.
Subpart J--Records and Reports 21 CFR Part 211.180 General requirements.
(a) Any production, control, or distribution record that is required to be maintained in compliance with this part and is specifically associated with a batch of a drug product shall be retained for at least 1 year after the expiration date of the batch.
19
20
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
11
Finding the Predicate Rules
Validation Center™ Copyright © 2021, ProPharma Group 21
Go to the FDA web site: www.fda.gov
Click on “Code of Federal Regulations”
Finding the Predicate Rules
Validation Center™ Copyright © 2021, ProPharma Group 22
This will bring up a search screen for 21 CFR
Type Part Number
ORSelect the
Part Number(s) from the list
21
22
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
12
Finding the Predicate Rules
Validation Center™ Copyright © 2021, ProPharma Group 23
This will bring up a listing of the regulation sections
Click here to see the entire regulation:
Or, on the specific sub-section you wantto see:
Some of the Major Guideline Documents
Validation Center™ Copyright © 2021, ProPharma Group24
Guidance for Industry
Computerized Systems Used in Clinical Investigations (2007)
Part 11, Electronic Records; Electronic Signatures – Scope and Application (2003)
General Principles of Software Validation; Final Guidance for Industry and FDA Staff (2002)
Blood Establishment Computer System Validation in the User’s Facility (2013)
Available on www.fda.gov
23
24
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
13
What Software Requires Validation?
Validation Center™ Copyright © 2021, ProPharma Group 25
What Types of Computer
Systems and Software Require
Validation?
Medical Device Software• Software used as a component, part, or accessory
of a medical device• Software that is itself a medical device
Source: General Principles of Software Validation: Final Guidance for Industry and FDA Staff
Examples: Medical Device Software
Validation Center™ Copyright © 2021, ProPharma Group 26
Medical Device SoftwareSoftware used as a component, part, or accessory of a medical device.
And, software that is itself a medical device.
Patient Monitoring Software
Infusion Pump Software
Robotic Surgery Software
Wheelchair and Scooter Software
Laboratory Diagnostics
Software
Hospital Bed Software
Injury Treatment Machine Software
Heart Arrhythmia Detection Software
Radiation Treatment Control
Software
Blood Donor Management
Software
Medical Imaging System Software
Blood Supply Management
Software
Laser Treatment Software
Defibrillator Software
Pacemaker Software
Oxygen Regulating Software
25
26
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
14
What Software Requires Validation?
Validation Center™ Copyright © 2021, ProPharma Group 27
What Types of Computer
Systems and Software Require
Validation?
Medical Device Software• Software used as a component, part, or accessory
of a medical device• Software that is itself a medical device
Production Software• Software used in the production of the FDA
regulated product
Source: General Principles of Software Validation: Final Guidance for Industry and FDA Staff
Examples: Production Software
Validation Center™ Copyright © 2021, ProPharma Group 28
Production SoftwareSoftware used in the production of the FDA regulated product
Laboratory Management
Software
Laboratory Instrument Software
Laboratory Calculations (e.g.,
spreadsheets)
Labeling SoftwareBuilding
Management Systems
Product Testing Software
Product/Part Inspection Software
Batch Release Software
Production MonitoringSoftware
Programmable Logic Controllers
(PLCs)
Computer Numerical
Controls (CNCs)
Manufacturing Automation
Software
Material Control Software
Bill of Material Software
Yield CalculationsWork Order
Management Software
27
28
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
15
What Software Requires Validation?
Validation Center™ Copyright © 2021, ProPharma Group 29
What Types of Computer
Systems and Software Require
Validation?
Medical Device Software• Software used as a component, part, or accessory
of a medical device• Software that is itself a medical device
Production Software• Software used in the production of the FDA
regulated product
Quality Management Software• Software used to implement the FDA-required
quality management system
Source: General Principles of Software Validation: Final Guidance for Industry and FDA Staff
Examples: Quality Management Systems
Validation Center™ Copyright © 2021, ProPharma Group 30
Preventive Maintenance Management
Inventory Control Software
(e.g., ERPs)
Document Management
Software
Calibration Software
CAPASoftware
ComplaintsSoftware
Non-Conformance Tracking Software
Deviation TrackingSoftware
Internal Audit TrackingSoftware
Change ControlSoftware
Device HistorySoftware
Specification Management
Software
Product Recall Management
Software
Product Returns Management
Software
Specification Setting Software
Quality Trending Software
Quality Management SoftwareSoftware used to implement the FDA-required quality management system
29
30
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
16
What Software Requires Validation?
Validation Center™ Copyright © 2021, ProPharma Group 31
What Types of Computer
Systems and Software Require
Validation?
Medical Device Software• Software used as a component, part, or accessory
of a medical device• Software that is itself a medical device
Source: Guidance for Industry Part 11, Electronic Records; Electronic Signatures — Scope and Application
Production Software• Software used in the production of the FDA
regulated product
Quality Management Software• Software used to implement the FDA-required
quality management system
Software for FDA-Regulated Records• Software used to create, modify, maintain, archive,
retrieve, or transmit FDA-required records. And electronic records submitted, per FDA requirement.
Examples: Records Software
Validation Center™ Copyright © 2021, ProPharma Group 32
Adverse Event Reporting Software
Service Records Software
DistributionRecords
Electronic Submissions
Software
Clinical Trial Records Software
Prescription Order Fulfilment Software
Warehouse Management
Software
IRB Records Software
Organ / Tissue Donor Records
Call Center Records Software
Training Records Software
Learning Management
Software
Supplier Approval Records
Validation Records
Software for FDA-Regulated RecordsAny software used to create, modify, maintain, archive, retrieve, or transmit
FDA-required records. And, electronic records submitted, per FDA requirement.
MDR Reporting Software
Product Rework Records
31
32
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
17
Which Needs Validation?
Validation Center™ Copyright © 2021, ProPharma Group33
B. A product complaint tracking system
D. Electronic records
submitted to the FDA for a New
Drug Application
(NDA)
F. Software used to
analyze brain scans for
Alzheimer’s detection
E. The accounting module of an ERP that also
tracks the quality status of each lot
C. System controlling the temperature of
a drug storage facility
A. Electronic records of
training on QA SOPs
Does it need validation?
Validation Center™ Copyright © 2021, ProPharma Group34
A. A spreadsheet used to
calculate the raw material quantities for a batch of drug
product
B. A spreadsheet used to calculate the number of
vacation days for each lab technician
C. An database used to track
laboratory results for clinical study patients
D. A database used to track
expected delivery dates for medical device parts
E. A document management system used to author and
approve employee performance reviews
F. A document management system used to author and
approve procedures for performing regulated tasks
?
33
34
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
18
1. Briefly describe what you have just learned about the FDA.
2. List some of the key regulations and guidelinesthat address computer system validation.
3. Which FDA predicate rules apply to your company?
4. What are some of the processes or records covered by your predicate rules where you use computerized systems?
Exercise #1
Validation Center™ Copyright © 2021, ProPharma Group 35
21 CFR Part 11 and Annex 11
Module 2
35
36
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
19
• Understand the basis for the regulation
• Identify the key aspects of 21 CFR Part 11
• Understand the 2003 guidance from the FDA regarding the scope of 21 CFR Part 11
• Awareness of Annex 11 and its applicability to US companies
Learning Objectives
Validation Center™ Copyright © 2021, ProPharma Group 37
Introduction 21 CFR 11 and Annex 11
Framework, Deliverables,,
& Plan
Requirements & Design
Validation Testing Evaluation
• In the early 1990’s, the industry was looking for guidance to move towards electronic documentation, so they asked FDA to provide some guidelines for electronic signatures.
• 1991 – Pharmaceutical industry members met with the FDA to determine how they could
accommodate paperless record systems under the current good manufacturing practice (CGMP) regulations in parts 210 and 211
• 1994– FDA published the proposed regulation
• 1997– Part 11 went into effect
History of Part 11
Validation Center™ Copyright © 2021, ProPharma Group 38
37
38
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
20
• 21 CFR Part 11 regulations set forth the criteria under which the FDA considers:
1. electronic records,
2. electronic signatures
3. handwritten signatures executed to electronic records
– to be trustworthy, reliable, and generally equivalent to paper records and handwritten signatures executed on paper.
• Part 11 was enacted to ensure the authenticity, integrity, and, when appropriate, the confidentiality of electronic records, and to ensure that the signer cannot readily repudiate the signed record as not genuine.
Importance of Part 11
Validation Center™ Copyright © 2021, ProPharma Group 39
21 CFR Part 11 Scope
Validation Center™ Copyright © 2021, ProPharma Group40
Part 11 applies to:
1. Records in electronic form that are created, modified, maintained, archived, retrieved, or transmitted, under any records requirements set forth in agency [FDA] regulations.
2. Electronic records submitted to the agency under requirements of the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act,even if such records are not specifically identified in agency regulations.
• However, this part does not apply to paper records that are, or have been, transmitted by electronic means.
39
40
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
21
• Definition 11.3 (b) (4) Closed System– An environment in which system access is controlled by persons who are
responsible for the content of electronic records that are on the system.
• Definition 11.3 (b) (9) Open System– An environment in which system access is not controlled by persons who are
responsible for the content of electronic records that are on the system.
• Definition 11.3 (b) (7) Electronic Record– Any combination of text, graphics, data, audio, pictorial, or other information
representation in digital form that is created, modified, maintained, archived, retrieved, or distributed by a computer system.
Part 11 Definitions
Validation Center™ Copyright © 2021, ProPharma Group 41
• Definition 11.3 (b) (7) Electronic Signature– A computer data compilation of any symbol or series of symbols executed, adopted,
or authorized by an individual to be the legally binding equivalent of the individual's handwritten signature.
• Definition 11.3 (b) (8) Handwritten Signature– The scripted name or legal mark of an individual handwritten by that individual and
executed or adopted with the present intention to authenticate a writing in a permanent form. The act of signing with a writing or marking instrument such as a pen or stylus is preserved. The scripted name or legal mark, while conventionally applied to paper, may also be applied to other devices that capture the name or mark.
• Definition 11.3 (b) (3) Biometrics– A method of verifying an individual's identity based on measurement of the
individual's physical feature(s) or repeatable action(s) where those features and/or actions are both unique to that individual and measurable.
Part 11 Definitions
Validation Center™ Copyright © 2021, ProPharma Group 42
41
42
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
22
Part 11 Controls
Validation Center™ Copyright © 2021, ProPharma Group 43
Controls for Electronic Records in Closed Systems
• Requirement 11.10 (a) Validation– Validation of systems to ensure accuracy, reliability, consistent intended
performance, and the ability to discern invalid or altered records.
• Requirement 11.10 (b) Copies for Review– The ability to generate accurate and complete copies of records in both human
readable and electronic form suitable for inspection, review, and copying by the agency.
• Requirement 11.10 (c) Record Protection– Protection of records to enable their accurate and ready retrieval throughout the
records’ retention period.
Procedures and Controls - Records
Validation Center™ Copyright © 2021, ProPharma Group 44
43
44
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
23
• Requirement 11.10 (d) Access– Limiting system access to authorized individuals.
• Requirement 11.10 (g) Authority Checks– Use of authority checks to ensure that only authorized individuals can use the
system, electronically sign a record, access the operation or computer system input or output device, alter a record, or perform the operation at hand.
Procedures and Controls - Records
Validation Center™ Copyright © 2021, ProPharma Group 45
• Requirement 11.10 (e) Audit Trails– Use of secure, computer-generated, time-stamped audit trails to independently
record the date and time of operator entries and actions that create, modify, or delete electronic records.
– Record changes shall not obscure previously recorded information.
– Such audit trail documentation shall be retained for a period at least as long as that required for the subject electronic records and shall be available for agency review and copying.
Procedures and Controls - Records
Validation Center™ Copyright © 2021, ProPharma Group 46
NOTE: Reason for change is not required by Part 11, but in many cases is required by the predicate rule
45
46
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
24
• Requirement 11.10 (f) System Checks– Use of operational system checks to enforce permitted sequencing of steps and
events, as appropriate.
• Requirement 11.10 (h) Device Checks– Use of device (e.g., terminal) checks to determine, as appropriate, the validity of the
source of data input or operational instruction.
Procedures and Controls - Records
Validation Center™ Copyright © 2021, ProPharma Group 47
Enter data Verify data entry Route for approval Report
Receive raw materials Test materials Release for use
Access only from appropriate domains
Input from equipment or instruments
• Requirement 11.10 (j) Personal Accountability– The establishment of, and adherence to, written policies that hold individuals
accountable and responsible for actions initiated under their electronic signatures, in order to deter record and signature falsification.
• Requirement 11.10 (i) Personnel Qualifications– Determination that persons who develop, maintain, or use electronic
record/electronic signature systems have the education, training, and experience to perform their assigned tasks.
Procedures and Controls - Records
Validation Center™ Copyright © 2021, ProPharma Group 48
• Review developer, tester, … Curriculum Vitae (resume)
• Require developer training before working on system
• Require user training before using system
• Implement record keeping for these activities
47
48
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
25
• Requirement 11.10 (k) Documentation Controls – Use of appropriate controls over systems documentation including:
1. Adequate controls over the distribution of, access to, and use of documentation for system operation and maintenance.
2. Revision and change control procedures to maintain an audit trail that documents time-sequenced development and modification of systems.
Procedures and Controls - Records
Validation Center™ Copyright © 2021, ProPharma Group 49
Part 11 Controls
Validation Center™ Copyright © 2021, ProPharma Group 50
Controls for Electronic SignaturesJohn Hancock
49
50
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
26
• Requirement 11.50 (a) Signature Components– Signed electronic records shall contain information associated with the signing that
clearly indicates all of the following:
1. The printed name of the signer;
2. The date and time when the signature was executed;
3. The meaning (such as review, approval, responsibility, or authorship) associated with the signature.
• Requirement 11.50 (b) Signature Components– The items, above, shall be subject to the same controls as for electronic records and
shall be included as part of any human readable form of the electronic record (such as electronic display or printout).
Procedures and Controls - Signatures
Validation Center™ Copyright © 2021, ProPharma Group 51
• Requirement 11.200 (a) Non-biometric Signatures– Non-biometric based signatures shall:
1. Employ at least two distinct identification components such as an identification code and password;
2. Be used only by their genuine owners;
3. Be administered and executed to ensure that attempted use of an individual’s electronic signature by anyone other than its genuine owner requires collaboration of two or more individuals.
• Requirement 11.200 (b) Biometric Signatures– Electronic signatures based upon biometrics shall be designed to ensure that they
cannot be used by anyone other than their genuine owners.
Procedures and Controls - Signatures
Validation Center™ Copyright © 2021, ProPharma Group 52
51
52
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
27
• Requirement 11.100 (a) Uniqueness– Each electronic signature shall be unique to one individual and shall not be reused
by, or reassigned to, anyone else.
• Requirement 11.300 (a) Uniqueness– Maintaining the uniqueness of each combined identification code and password,
such that no two individuals have the same combination of identification code and password.
• Requirement 11.300 (b) Periodic Checks– Ensuring that identification code and password issuances are periodically checked,
recalled, or revised.
• Requirement 11.300 (d) Reporting of Attempted Unauthorized Use– Use of transaction safeguards to prevent unauthorized use of passwords and/or
identification codes, and to detect and report in an immediate and urgent manner any attempts at their unauthorized use to the system security unit, and, as appropriate, to organizational management.
Procedures and Controls - Signatures
Validation Center™ Copyright © 2021, ProPharma Group 53
• Requirement 11.300 (c) Compromised Tokens– Following loss management procedures to electronically deauthorize lost, stolen,
missing, or otherwise potentially compromised tokens, cards, and other devices that bear or generate identification code or password information, and to issue temporary or permanent replacements using suitable, rigorous controls.
• Requirement 11.300 (e) Testing of Tokens– Initial and periodic testing of devices, such as tokens or cards, that bear or generate
identification code or password information to ensure that they function properly and have not been altered in an unauthorized manner.
Procedures and Controls - Signatures
Validation Center™ Copyright © 2021, ProPharma Group 54
53
54
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
28
• Requirement 11.100 (b) Personnel Identification– Before an organization establishes, assigns, certifies, or otherwise sanctions an
individual’s electronic signature, or any element of such electronic signature, the organization shall verify the identity of the individual.
• Requirement 11.100 (c) Certification– Persons using electronic signatures shall, prior to or at the time of such use, certify to
the agency that the electronic signatures in their system, used on or after August 20, 1997, are intended to be the legally binding equivalent of traditional handwritten signatures.
Procedures and Controls - Signatures
Validation Center™ Copyright © 2021, ProPharma Group 55
• Requirement 11.70 Signature/Record Linking– Electronic signatures and handwritten signatures executed to electronic records shall
be linked to their respective electronic records to ensure that the signatures cannot be excised, copied, or otherwise transferred to falsify an electronic record by ordinary means.
Procedures and Controls - Signatures
Validation Center™ Copyright © 2021, ProPharma Group 56
55
56
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
29
Part 11 Controls
Validation Center™ Copyright © 2021, ProPharma Group 57
Controls for Electronic Records in Open Systems
• Requirement 11.30 Open System Controls– Persons who use open systems to create, modify, maintain, or transmit electronic
records shall employ procedures and controls designed to ensure the authenticity, integrity, and, as appropriate, the confidentiality of electronic records from the point of their creation to the point of their receipt.
– Such procedures and controls shall include those identified in 11.10 [closed systems], as appropriate, and additional measures such as document encryption and use of appropriate digital signature standards to ensure, as necessary under the circumstances, record authenticity, integrity, and confidentiality.
Procedures and Controls – Open Systems
Validation Center™ Copyright © 2021, ProPharma Group 58
Open System - Definition
An environment where system access is not controlled by persons who are responsible for the content of the electronic records that are
on the system
57
58
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
30
• Final 21 CFR Part 11 regulation was published in 1997
• Several detailed FDA guidelines followed – E.g., time stamps (time zone issues, etc.), COTS software, audit trails
• In February 2003 FDA stunned the industry by announcing that all Part 11 guidelines were withdrawn, and the agency was re-evaluating the Part 11 regulation.
• A new Part 11 Guidance Document was published at this time.
The Shock
Validation Center™ Copyright © 2021, ProPharma Group 59
• Read the 2003 FDA Guidance
• Highlight Key Points
• Answer the questions in the student worksheet
• Return to class in 20 minutes and we will discuss the document
Exercise #2
Validation Center™ Copyright © 2021, ProPharma Group 60
“Electronic Records; Electronic Signatures - Scope and Application”
59
60
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
31
• The FDA realized that Part 11 was dampening technical progress.
• Rigorous enforcement and compliance with the requirements was preventing many new applications from seeing the light of day. Industry interpretation:
– Restricted use of electronic technology
– Discouraged innovation and technological advances• Especially FDA’s PAT (Process Analytical Technology) initiative
– Significantly increased costs
• The FDA has said that a new version of Part 11 is coming– We’re still waiting…
Why Redirect Part 11?
Validation Center™ Copyright © 2021, ProPharma Group 61
Predicate Rules vs. Part 11
Validation Center™ Copyright © 2021, ProPharma Group 62
21 CFR 820Quality System Regulation
(Medical Device GMP)
21 CFR 211Current Good Manufacturing Practice
for Finished Pharmaceuticals
21 CFR 58Good Laboratory Practice for
Nonclinical Laboratory Studies
21 CFR 600Biological Products: General
21 CFR 606Current Good Manufacturing Practice
for Blood and Blood Components
21 CFR 50Protection of Human Subjects
Predicate Rules, examples
Predicate Rules contain product-specific requirements(whether paper/manual or electronic/automated)
• Processes and business rules• Data transmissions to FDA
• Records and data• Record retention time
Part 11 contains specific requirements for ALL electronic records and signatures
61
62
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
32
Part 11 applies to:
21 CFR Part 11 Scope - Clarified
Validation Center™ Copyright © 2021, ProPharma Group 63
1. Records that are required to be maintained under predicate rule requirements and that are maintained in electronic format in place of paper format.
• NOTE: Records (and any associated signatures) that are not required to be retained under predicate rules, but that are nonetheless maintained in electronic format, are not Part 11 records.
2. Records that are required to be maintained under predicate rules, that are maintained in electronic format in addition to paper format, and that are relied on to perform regulated activities.
Part 11 applies to:
21 CFR Part 11 Scope - Clarified
Validation Center™ Copyright © 2021, ProPharma Group 64
3. Records submitted to the FDA under predicate rules in electronic format.
• NOTE: A record that is not itself submitted, but is used in generating a submission, is not a Part 11 record unless it is otherwise required to be maintained under predicate rule and is maintained in electronic format.
4. Electronic signatures that are intended to be the equivalent of handwritten signatures, initials, and other general signings required by predicate rules. Part 11 signatures include electronic signatures that are used, for example, to document the fact that certain events or actions occurred in accordance with the predicate rule (e.g. approved, reviewed, and verified).
63
64
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
33
• FDA intends to enforce predicate rule requirements for records within the scope of 21 CFR Part 11
• FDA intends to interpret Part 11 narrowly – Fewer records than originally thought are within the scope of Part 11
– Records and associated signatures that are not required to be retained by predicate rules are not considered to be within the scope of Part 11
– If an electronic record is created that is not required by predicate rules to be retained, then Part 11 does not apply (intermediate drafts)
– If a system is merely incidental to creating another form of the record, then Part 11 does not apply (the typewriter rule – once the letter is typed, no one cares about the typewriter)
Guidance: Narrow Interpretation
Validation Center™ Copyright © 2021, ProPharma Group 65
• FDA will not normally take regulatory action to enforce compliance with the Part 11 requirements for
– Validation
– Audit trail
– Record retention
– Record copying requirements
• As long as the electronic records are maintained in accordance with the underlying regulatory requirements (aka. Predicate rules)
Guidance: Enforcement Discretion
Validation Center™ Copyright © 2021, ProPharma Group 66
65
66
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
34
• FDA will not normally take regulatory action to enforce compliance with the Part 11 requirements for
– Validation
– Audit trail
– Record retention
– Record copying requirements
• As long as the electronic records are maintained in accordance with the underlying regulatory requirements (aka. Predicate rules)
Guidance: Enforcement Discretion
Validation Center™ Copyright © 2021, ProPharma Group 67
The FDA recommends that that your decision to validate computerized systems, and the
extent of the validation, take into account the impact the systems have on your ability to
meet predicate rule requirements.
You should also consider the impact those systems might have on the accuracy,
reliability, integrity, availability, and authenticityof required records and signatures.
• FDA will not normally take regulatory action to enforce compliance with the Part 11 requirements for
– Validation
– Audit trail
– Record retention
– Record copying requirements
• As long as the electronic records are maintained in accordance with the underlying regulatory requirements (aka. Predicate rules)
Guidance: Enforcement Discretion
Validation Center™ Copyright © 2021, ProPharma Group 68
The FDA recommends that you base your decision on whether to apply audit
trails on the need to comply with predicate rule requirements, ajustified and documented risk
assessment, and a determination of the potential effect on product
quality and safety and record integrity.
67
68
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
35
• FDA will not normally take regulatory action to enforce compliance with the Part 11 requirements for
– Validation
– Audit trail
– Record retention
– Record copying requirements
• As long as the electronic records are maintained in accordance with the underlying regulatory requirements (aka. Predicate rules)
Guidance: Enforcement Discretion
Validation Center™ Copyright © 2021, ProPharma Group 69
The FDA recommends that your decision on how to maintain records be based on
predicate rule requirements and that you base your decision on a justified and documented risk assessment and a determination of the
value of the records over time.
The FDA does not intend to object if you decide to archive required records in
electronic format to non-electronic media such as microfilm, microfiche, and paper, or
to a standard electronic file format (examples of such formats include, but are not limited to,
PDF, XML, or SGML).
• FDA will not normally take regulatory action to enforce compliance with the Part 11 requirements for
– Validation
– Audit trail
– Record retention
– Record copying requirements
• As long as the electronic records are maintained in accordance with the underlying regulatory requirements (aka. Predicate rules)
Guidance: Enforcement Discretion
Validation Center™ Copyright © 2021, ProPharma Group 70
The FDA recommends that you supply copies of electronic records by:
• Producing copies of records held in common portable formats when records are maintained in these formats
• Using established automated conversion or export methods, where available, to make copies in a more common format (examples of such formats include, but are not limited to, PDF, XML, or SGML)
69
70
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
36
• FDA intends to enforce provisions related to the following controls– Limiting system access to authorized individuals
– Use of operational system checks
– Use of authority checks
– Use of device checks
– Determination that persons who develop, maintain, or use electronic systems have the education, training, and experience to perform their assigned tasks
– Establishment of and adherence to written policies that hold individuals accountable for actions initiated under their electronic signatures
– Appropriate controls over systems documentation
– Controls for open systems
– Controls for Electronic Signatures
Guidance: Intent to Enforce
Validation Center™ Copyright © 2021, ProPharma Group 71
Annex 11 Timeline
Copyright © 2021, ProPharma Group 72
• Annex 11 in effect as part of EudraLex
2011 (revision)
1990 2000 2010 201520051995
2013
1990 2000 2010 201520051995
• Annex 11 adoption by PIC/S
1992 (original version)
Validation Center™
71
72
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
37
To Which Companies Does Annex 11 Apply?
Copyright © 2021, ProPharma Group 73
Companies that manufacture*• Purchase/receipt of materials• Production • Filling• Labelling
• Quality Control• Release• Storage• Distribution
*
medicinal products** for human or veterinary use• Pharmaceuticals• Radio-pharmaceuticals• Biological products• Blood/Plasma based products
• Vaccines• Homeopathic medicinal products• Herbal medicinal products• Advanced therapies
**
Validation Center™
Annex 11 Definitions
Copyright © 2021, ProPharma Group 74
Computerised System
A system including the input of data, electronic processing and the output of information to be used either for reporting or automatic control
ApplicationSoftware installed on a defined
platform/hardware providing specific functionality
IT InfrastructureThe hardware and software such as networking software and operation
systems, which makes it possible for the application to function
Bespoke/Customised
A computerised system individually designed to suit a
specific business process
Commercial off the Shelf Software commercially
available, whose fitness for use is demonstrated by a broad spectrum of users
aka. COTS
Validation Center™
73
74
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
38
Annex 11 Definitions
Copyright © 2021, ProPharma Group 75
Process Owner
The person responsible for the business
process
System Owner
The person responsible for the availability,
and maintenanceof a computerised
system and for the security of
the data residing on that system
Third Party
Parties not directly managed by
the holder of the
manufacturing and/or import authorisation
Validation Center™
• There should be close cooperation between all relevant personnel such as Process Owner, System Owner, Authorised Persons and IT.
• All personnel should have – appropriate qualifications
– Appropriate level of access
– defined responsibilities to carry out their assigned duties
Personnel [Annex 11 Section 2]
Validation Center™ Copyright © 2021, ProPharma Group 76
75
76
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
39
• Risk management should be applied throughout the lifecycle of the computerised system taking into account patient safety, data integrity and product quality.
• Decisions on the extent of validation and data integrity controls should be based on a justified and documented risk assessment of the computerisedsystem.
Risk Management [Annex 11 Section 1]
Validation Center™ Copyright © 2021, ProPharma Group 77
• An up-to-date listing of all relevant systems and their GMP functionality (inventory) should be available.
Validation [Annex 11 Section 4]
Validation Center™ Copyright © 2021, ProPharma Group 78
Example
77
78
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
40
• The validation documentation and reports should cover the relevant steps of the life cycle.
• Should be able to justify standards, protocols, acceptance criteria, procedures and records based on their risk assessment.
Validation [Annex 11 Section 4]
Validation Center™ Copyright © 2021, ProPharma Group 79
UserRequirementsSpecification
Functional RequirementsSpecifications
DesignSpecifications
PerformanceQualificationTests (PQ)
OperationalQualificationTests (OQ)
InstallationQualificationTests (IQ)
SystemBuild
Verifies
Verifies
Verifies
Planning Reporting
Verifies
• User Requirements Specifications should describe the required functions of the computerised system and be based on documented risk assessment and GMP impact.
• User requirements should be traceable throughout the life-cycle.
Validation [Annex 11 Section 4]
Validation Center™ Copyright © 2021, ProPharma Group 80
79
80
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
41
• For critical systems, an up-to-date system description detailing – the physical and logical arrangements
– data flows
– interfaces with other systems or processes
– hardware
– software pre-requisites
– security measures
Validation [Annex 11 Section 4]
Validation Center™ Copyright © 2021, ProPharma Group 81
• The regulated user should take all reasonable steps to ensure that the system has been developed in accordance with an appropriate quality management system.
• The supplier should be assessed appropriately.
• Documentation supplied with Commercial-off-the-Shelf products should be reviewed by regulated users to check that user requirements are fulfilled.
Validation [Annex 11 Section 4]
Validation Center™ Copyright © 2021, ProPharma Group 82
81
82
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
42
• For the validation of bespoke or customised computerised systems there should be a process in place that ensures the formal assessment and reporting of quality and performance measures for all the life-cycle stages of the system.
Validation [Annex 11 Section 4]
Validation Center™ Copyright © 2021, ProPharma Group 83
• Evidence of appropriate test methods and test scenarios should be demonstrated. Particularly, system parameter limits, data limits and error handling should be considered.
• Automated testing tools and test environments should have documented assessments for their adequacy.
Validation [Annex 11 Section 4]
Validation Center™ Copyright © 2021, ProPharma Group 84
83
84
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
43
• Validation documentation should include change control records (if applicable) and reports on any deviations observed during the validation process.
Validation [Annex 11 Section 4]
Validation Center™ Copyright © 2021, ProPharma Group 85
• If data are transferred to another data format or system, validation should include checks that data are not altered in value and/or meaning during this migration process.
Validation [Annex 11 Section 4]
Validation Center™ Copyright © 2021, ProPharma Group 86
85
86
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
44
• Computerised systems exchanging data electronically with other systems should include appropriate built-in checks for the correct and secure entry and processing of data, in order to minimize the risks.
• For critical data entered manually, there should be an additional check on the accuracy of the data. This check may be done by a second operator or by validated electronic means.
• The criticality and the potential consequences of erroneous or incorrectly entered data to a system should be covered by risk management.
Data [Annex 11 Section 5]
Validation Center™ Copyright © 2021, ProPharma Group 87
• Consideration should be given, based on a risk assessment, to building into the system the creation of a record of all GMP-relevant changes and deletions (a system generated "audit trail").
• For change or deletion of GMP-relevant data the reason should be documented.
• Audit trails need to be available and convertible to a generally intelligible form and regularly reviewed.
Audit Trails [Annex 11 Section 9]
Validation Center™ Copyright © 2021, ProPharma Group 88
87
88
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
45
• Stored data should be checked for accessibility, readability and accuracy.
• Access to data should be ensured throughout the retention period.
• Regular back-ups of all relevant data should be done.
• Integrity and accuracy of backup data and the ability to restore the data should be checked during validation and monitored periodically.
• Data should be secured by both physical and electronic means against damage.
Data Storage [Annex 11 Section 7]
Validation Center™ Copyright © 2021, ProPharma Group 89
• Data may be archived.
• This data should be checked for accessibility, readability and integrity.
• If relevant changes are to be made to the system (e.g. computer equipment or programs), then the ability to retrieve the data should be ensured and tested.
Data Archival [Annex 11 Section 17]
Validation Center™ Copyright © 2021, ProPharma Group 90
89
90
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
46
• Physical and/or logical controls should restrict access to computerisedsystem to authorised persons.
• Suitable methods of preventing unauthorised entry may include – Keys
– Pass cards
– Personal codes with passwords
– Biometrics
– Restricted access to computer equipment and data storage areas.
• The extent of security controls depends on the criticality of the computerisedsystem.
Security [Annex 11 Section 12]
Validation Center™ Copyright © 2021, ProPharma Group 91
• Management systems for data and for documents should be designed to record the identity of operators.
• Creation, change, and cancellation of access authorisations should be recorded.
Security [Annex 11 Section 12]
Validation Center™ Copyright © 2021, ProPharma Group 92
91
92
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
47
• Electronic records may be signed electronically.
• Electronic signatures are expected to:a) have the same impact as hand-written signatures within the boundaries of the
company,
b) be permanently linked to their respective record,
c) include the time and date that they were applied.
Electronic Signatures [Annex 11 Section 14]
Validation Center™ Copyright © 2021, ProPharma Group 93
• When a computerised system is used for recording certification and batch release,
– the system should allow only Authorised Persons to certify the release of the batches
– and it should clearly identify and record the person releasing or certifying the batches.
– This should be performed using an electronic signature.
Batch Release [Annex 11 Section 14]
Validation Center™ Copyright © 2021, ProPharma Group 94
93
94
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
48
• It should be possible to obtain clear printed copies of electronically stored data.
• For records supporting batch release, printouts should indicate if any of the data has been changed since the original entry.
Print Outs [Annex 11 Section 14]
Validation Center™ Copyright © 2021, ProPharma Group 95
• All incidents, not only system failures and data errors, should be reported and assessed.
• The root cause of a critical incident should be identified and should form the basis of corrective and preventive actions.
Incident Management [Annex 11 Section 13]
Validation Center™ Copyright © 2021, ProPharma Group 96
95
96
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
49
• Any changes to a computerised system, including system configurations, should only be made in a controlled manner in accordance with a defined procedure.
Change Management [Annex 11 Section 10]
Validation Center™ Copyright © 2021, ProPharma Group 97
• For the availability of computerised systems supporting critical processes, provisions should be made to ensure continuity of support for those processes in the event of a system breakdown (e.g. a manual or alternative system).
• The time required to bring the alternative arrangements into use should be based on risk and appropriate for a particular system and the business process it supports.
• These arrangements should be adequately documented and tested.
Business Continuity [Annex 11 Section 16]
Validation Center™ Copyright © 2021, ProPharma Group 98
97
98
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
50
• Computerised systems should be periodically evaluated to confirm that they remain in a valid state and are compliant with GMP.
• Such evaluations should include, where appropriate, – the current range of functionality
– deviation records
– incidents
– problems
– performance
– reliability
– security
– upgrade history
– validation status reports
Periodic Evaluation [Annex 11 Section 11]
Validation Center™ Copyright © 2021, ProPharma Group 99
Suppliers and Service Providers include third parties that…
• provide, install, configure, integrate, validate, maintain (e.g. via remote access), modify or retain a computerised system or related service or for data processing
Suppliers & Service Provider [Annex 11 Section 3]
Validation Center™ Copyright © 2021, ProPharma Group 100
Third Party
Parties not directly managed
by the holder of the manufacturing
and/or import authorisation
99
100
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
51
• When third parties (e.g. suppliers, service providers) are used, formal agreements must exist between the parties, and these agreements should include clear statements of the responsibilities of the third party.
• IT-departments should be considered analogous.
• The competence and reliability of a supplier are key factors when selecting a product or service provider.
• The need for an audit should be based on a risk assessment.
• Quality system and audit information relating to suppliers or developers of software and implemented systems should be made available to inspectors on request.
Suppliers & Service Provider [Annex 11 Section 3]
Validation Center™ Copyright © 2021, ProPharma Group 101
Computer System Validation Framework, Deliverables, & PlanModule 3
101
102
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
52
1. Overview of popular software development life cycles
2. Overview of the computer system validation process
3. Learn the purpose and contents of the Validation Plan
Objectives
Validation Center™ Copyright © 2021, ProPharma Group 103
UserRequirementsSpecification
FunctionalSpecifications
DesignSpecifications
PerformanceQualificationTests (PQ)
OperationalQualificationTests (OQ)
InstallationQualification
Tests (IQ)
SystemBuild
Verifies
Verifies
Verifies
Planning ReportingVerifies
Introduction 21 CFR 11 and Annex 11
Framework,Deliverables,
& Plan
Requirements & Design
Validation Testing Evaluation
Systems Development Life Cycle (SDLC)
Validation Center™ Copyright © 2021, ProPharma Group 104
Key Deliverables
Understand theBusinessProblem orOpportunity
Develop anInformationSystemSolution
ImplementInformationSystemSolution
• User RequirementsSystems Investigation
• Functional RequirementsSystems Analysis
• System SpecificationsSystems Design
• Operational SystemSystems Implementation
• Improved SystemSystems Maintenance
103
104
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
53
• Very common
• Approach:1. Start with a general idea of what you want
2. Use informal design and coding tools
3. Work until it is done
• Not appropriate for FDA regulated systems and applications due tolack of structure and documentation
Code-and-Fix
Validation Center™ Copyright © 2021, ProPharma Group 105
Waterfall Model
Validation Center™ Copyright © 2021, ProPharma Group 106
• Classic IT Software Development Life Cycle
• All the planning is done up front
• Project progresses through an orderly sequence of steps from initial concept through testing
• Document driven
• Deliverables are reviewed at the end of each step before the next step begins
Works well in environments with well-understood technologies and stable project definitions
105
106
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
54
Each iteration involves six steps:
1. Determine objective, alternatives and constraints
2. Identify and resolve risks
3. Evaluate alternatives
4. Develop the deliverables for that iteration and verify that they are correct
5. Plan the next iteration
6. Commit to an approach for the next iteration
Spiral Model of Software Development
Validation Center™ Copyright © 2021, ProPharma Group 107
Useful when you’re not sure exactly sure up front what you’re building
Agile Model of Software Development
Validation Center™ Copyright © 2021, ProPharma Group 108
Iteration -1
Project Selection
Iteration 0 (Warm Up)
Project Initiation
Iterations 1-N
Construction
Iteration 1-N
Production Operation &
Support
•Engage stakeholders
•Prioritize potential projects
•Determine Project feasibility
•Develop project vision
•Active stakeholder participation
•Obtain funding
•Form team
•Envision requirements and architecture
•Set up environment
Iterations 1-N(End Game)
Release Deployment
•Active stakeholder participation
•Collaborative development
•Model storming
•Test driven design
•Confirmatory testing
•Evolving documentation
•Active stakeholder participation
•Final system testing
•Final acceptance testing
•Train users and support staff
•Deploy into production
•Operate the system
•Support the system
•Identify defects and enhancements
Start work on release N+1
Provides frequent delivery of small, incremental functionality
107
108
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
55
CSV Model
Validation Center™ Copyright © 2021, ProPharma Group 109
UserRequirementsSpecification
FunctionalSpecifications
DesignSpecifications
PerformanceQualificationTests (PQ)
OperationalQualificationTests (OQ)
InstallationQualification
Tests (IQ)
SystemBuild
Verifies
Verifies
Verifies
Planning ReportingVerifies
Validation Plan• Scope• Approach• Roles &
Responsibilities• Acceptance Criteria
Planning
CSV Methodology
CSV Model
Validation Center™ Copyright © 2021, ProPharma Group 110
UserRequirementsSpecification
FunctionalSpecifications
DesignSpecifications
PerformanceQualificationTests (PQ)
OperationalQualificationTests (OQ)
InstallationQualification
Tests (IQ)
SystemBuild
Verifies
Verifies
Verifies
Planning ReportingVerifies
User Requirements• User Needs for the
software• Intended Use of the
Software• Critical Constraints
UserRequirementsSpecification
CSV Methodology
109
110
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
56
CSV Model
Validation Center™ Copyright © 2021, ProPharma Group 111
UserRequirementsSpecification
FunctionalSpecifications
DesignSpecifications
PerformanceQualificationTests (PQ)
OperationalQualificationTests (OQ)
InstallationQualification
Tests (IQ)
SystemBuild
Verifies
Verifies
Verifies
Planning ReportingVerifies
Functional Specification• How the software
should look• What data the software
should capture• Logic, calculations
FunctionalSpecifications
CSV Methodology
CSV Model
Validation Center™ Copyright © 2021, ProPharma Group 112
UserRequirementsSpecification
FunctionalSpecifications
DesignSpecifications
PerformanceQualificationTests (PQ)
OperationalQualificationTests (OQ)
InstallationQualification
Tests (IQ)
SystemBuild
Verifies
Verifies
Verifies
Planning ReportingVerifies
Design Specification• Database design• Process design• Security design• Interface design• Architecture design• Network requirements
DesignSpecifications
CSV Methodology
111
112
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
57
CSV Model
Validation Center™ Copyright © 2021, ProPharma Group 113
UserRequirementsSpecification
FunctionalSpecifications
DesignSpecifications
PerformanceQualificationTests (PQ)
OperationalQualificationTests (OQ)
InstallationQualification
Tests (IQ)
SystemBuild
Verifies
Verifies
Verifies
Planning ReportingVerifies
Develop Software /or/ Purchase and Configure
SystemBuild
CSV Methodology
CSV Model
Validation Center™ Copyright © 2021, ProPharma Group 114
UserRequirementsSpecification
FunctionalSpecifications
DesignSpecifications
PerformanceQualificationTests (PQ)
OperationalQualificationTests (OQ)
InstallationQualification
Tests (IQ)
SystemBuild
Verifies
Verifies
Verifies
Planning ReportingVerifies
InstallationQualification
Tests (IQ)
Installation Qualification• Installation and Set Up
instructions• Confirmation that
installed and set up according to Design
CSV Methodology
113
114
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
58
CSV Model
Validation Center™ Copyright © 2021, ProPharma Group 115
UserRequirementsSpecification
FunctionalSpecifications
DesignSpecifications
PerformanceQualificationTests (PQ)
OperationalQualificationTests (OQ)
InstallationQualification
Tests (IQ)
SystemBuild
Verifies
Verifies
Verifies
Planning ReportingVerifies
OperationalQualificationTests (OQ)
Operational Qualification• Confirmation that all
functionality is present• Confirmation that all
feature are working as specified
CSV Methodology
CSV Model
Validation Center™ Copyright © 2021, ProPharma Group 116
UserRequirementsSpecification
FunctionalSpecifications
DesignSpecifications
PerformanceQualificationTests (PQ)
OperationalQualificationTests (OQ)
InstallationQualification
Tests (IQ)
SystemBuild
Verifies
Verifies
Verifies
Planning ReportingVerifies
PerformanceQualification
Tests (PQ)
Performance Qualification• Confirmation that
software meets the users’ needs and is suitable for their use
CSV Methodology
115
116
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
59
CSV Model
Validation Center™ Copyright © 2021, ProPharma Group 117
UserRequirementsSpecification
FunctionalSpecifications
DesignSpecifications
PerformanceQualificationTests (PQ)
OperationalQualificationTests (OQ)
InstallationQualification
Tests (IQ)
SystemBuild
Verifies
Verifies
Planning ReportingVerifies
Reporting
Validation Report• Confirmation of
Validation Plan• Testing Summary• Confirmation that
Acceptance Criteria Met• Authorize Deployment
Verifies
CSV Methodology
• Common Objectives– High quality software
– Satisfied users
• Common Deliverables– Requirements
– Designs
– Tests
• Concurrent Timelines– Validation occurs during the SDLC or SALC
Relationship Between SDLC and CSV
Validation Center™ Copyright © 2021, ProPharma Group 118
117
118
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
60
CSV Deliverables – Custom Development
Validation Center™ Copyright © 2021, ProPharma Group 119
• Functional Specification (FS)
• Risk Assessment• Validation Plan
• System Design Specification• Executable System• Unit Testing, Integration Testing• IQ, OQ, PQ scripts• Traceability Matrices
• Change Control
• Archive
Software Life Cycle
Investigate Analyze Design Test Implement Maintain Retire
• User RequirementsSpecification (URS)
• Executed IQ,OQ, PQ Scripts
• Validation Report
• SOPs• User Training• Validated System
in Production
CSV Deliverables – Purchased Software
Validation Center™ Copyright © 2021, ProPharma Group 120
• Functional Specification (FS)
• Risk Assessment• Validation Plan
• System Design Specification• Configured System• IQ, OQ, PQ scripts• Traceability Matrices
• Change Control
• Archive
Software Life Cycle
Investigate Analyze Design Test Implement Maintain Retire
• User RequirementsSpecification (URS)
• Vendor Audit
• Executed IQ,OQ, PQ Scripts
• Validation Report
• SOPs• User Training• Validated System
in Production
119
120
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
61
Verifies
The “Bookends” for Validation Work
Validation Center™ Copyright © 2021, ProPharma Group 121
System Validation Work
What we will do
during validation
Planning ReportingVerifies
ValidationPlan
ValidationReport
What we did
during validation
The Process of Validation
1. What is the scope and approach?
2. What activities will be performed in testing the system?
3. Who is responsible for each step?
4. Schedule of validation activities
5. Validation deliverables
The Plan includes information on…
1. What tests will be conducted?
2. What is the architecture of the test environment?
3. What is the exact version of the software and hardware being validated?
4. How will we know that all of the functionality is tested?
5. How the tests will be written and approved?
6. How the testing will be conducted?
7. How the incidents during testing will be handled?
8. How the results of the testing will be summarized and approved?
Validation Plan
Validation Center™ Copyright © 2021, ProPharma Group 122
ValidationPlan
121
122
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
62
1. Why is it important to understand both the Software Development (or Acquisition) Life Cycle and the Software Validation process?
2. In software validation the intent of the PQ is to verify _________, and the intent of the OQ is to verify _________.
3. Which 2 software validation deliverables are the bookends of the process and should be written with an external reviewer in mind?
Exercise #3
Validation Center™ Copyright © 2021, ProPharma Group 123
• Download a copy of these documents– FDA Guidance – Computerized Systems Used in Clinical Investigations
– FDA Guidance – General Principles of Software Validation
• Read the documents
• Highlight key points
• Answer the questions in the student worksheet
Homework: Guidance Documents
Validation Center™ Copyright © 2021, ProPharma Group 124
Documents can be found on either• www.fda.gov• www.validationcenter.com/icsv-resources/
123
124
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
63
Welcome to Part 2Introduction
Agenda
Validation Center™ Copyright © 2021, ProPharma Group 126
Part 1 Introduction FDA Introduction
BREAK (20 minutes)
21 CFR 11 and Annex11 CSV Framework, Deliverables,
& Plan
Homework: FDA Guidance Documents
Part 2 Review Homework Requirements and Design
BREAK (20 minutes)
Validation Testing Final Exam (30 minutes) Review Exam Answers Wrap up
Introduction 21 CFR 11 and Annex 11
Framework, Deliverables,
& Plan
Requirements & Design
Validation Testing Evaluation
125
126
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
64
FDA Guidance
Validation Center™ Copyright © 2021, ProPharma Group 127
Audience
• Clinical trial sponsors
• Contract research organizations (CROs)
• Data management centers
• Clinical investigators
• Institutional review boards (IRBs)
Use
• Supplements the Guidance for Industry on Part 11, Electronic Records; Electronic Signatures — Scope and Application
Intended Audience and Use
Validation Center™ Copyright © 2021, ProPharma Group 128
127
128
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
65
• Standard Operating Procedures (SOPs)
• Source Documentation & Retention– Observations recorded directly into a system are “source documentation”
– Records must be retained for the time specified in the regulations (e.g., 21 CFR 312, 21 CFR 812)
• Audit Trails– Use computer-generated, time-stamped audit trails to capture record creation,
modification, and deletion
– Use the audit trail to verify data quality, integrity, and compliance
Recommendations
Validation Center™ Copyright © 2021, ProPharma Group 129
HOMEWORK #1What are 3 recommendations to ensure that a computer system used in clinical
investigations is in compliance?
• Access Limitations– Each system user should have an individual account
– Users should work only under their own password and not share their password with others
– Passwords should be changed at established intervals commensurate with a documented risk assessment
– System should limit the number of log-in attempts and record unauthorized access log-in attempts
Recommendations
Validation Center™ Copyright © 2021, ProPharma Group 130
HOMEWORK #1What are 3 recommendations to ensure that a computer system used in clinical
investigations is in compliance?
129
130
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
66
• Access Limitations– Users should log-in at the beginning of a data entry session and log-out at the
completion of the data entry session
– When user leaves a workstation, the person should log-out• Alternatively, an automatic log off can be appropriate for long idle periods
• For short periods of inactivity, use automatic protection to prevent unauthorized data entry (e.g., an automatic screen saver can prevent data entry until a password is entered)
Recommendations
Validation Center™ Copyright © 2021, ProPharma Group 131
HOMEWORK #1What are 3 recommendations to ensure that a computer system used in clinical
investigations is in compliance?
• Date and Time Stamps– Limit the ability to change the date or time to authorized personnel
– Always document changes to date or time
– For systems that span different time zones, implement time stamps with a clear understanding of the time zone reference used
– Ensure that system documentation explains time zone references, time zone acronyms, and other time zone naming conventions
Recommendations
Validation Center™ Copyright © 2021, ProPharma Group 132
HOMEWORK #1What are 3 recommendations to ensure that a computer system used in clinical
investigations is in compliance?
131
132
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
67
• External Access Controls– Prevent, detect, and mitigate effects of computer viruses, worms, or other potentially
harmful software code
– Prevent the altering, browsing, querying, or reporting of data via external software applications from outside the protective system software
– Retain records that indicate, for any point in time, the names of authorized personnel, their titles, and a description of their access privileges
• Available for inspection by FDA investigators
Recommendations
Validation Center™ Copyright © 2021, ProPharma Group 133
HOMEWORK #1What are 3 recommendations to ensure that a computer system used in clinical
investigations is in compliance?
• Data Entry Features– Use prompts, flags, or other helpful features to alert the user when data is outside of
the acceptable range
– Do not use features that automatically enter data into a field when the field is bypassed (default entries)
• Back-Ups– Regularly back up records to prevent loss
– Store back-up records at a secure location specified in an SOP, either offsite or in a separate building
– Maintain backup and recovery logs
Recommendations
Validation Center™ Copyright © 2021, ProPharma Group 134
HOMEWORK #1What are 3 recommendations to ensure that a computer system used in clinical
investigations is in compliance?
133
134
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
68
• Personnel Training– Train individuals in the specific operations they will perform in the computerized
systems
– Ensure that training is conducted by qualified individuals on a continuing basis
– Document the computer education, training, and experience
Recommendations
Validation Center™ Copyright © 2021, ProPharma Group 135
HOMEWORK #1What are 3 recommendations to ensure that a computer system used in clinical
investigations is in compliance?
• System Change Control– Changes include: software upgrades, security and performance patches, equipment
changes, component replacement, and new instrumentation
– Document all changes to the system
– Evaluate the effects of any changes to the system.
– Validate changes that exceed previously established operational limits or design specifications
– Train personnel on changes
Recommendations
Validation Center™ Copyright © 2021, ProPharma Group 136
HOMEWORK #1What are 3 recommendations to ensure that a computer system used in clinical
investigations is in compliance?
135
136
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
69
• Validation and testing
• System setup/installation
• System operation
• Computer user training
• System maintenance (including decommissioning)
• Data backup, recovery, and contingency plans
• System security measures
• Change control
• Data collection and handling (including data archiving, audit trails, and risk assessment)
• Alternative recording methods (when system is unavailable)
• Roles and responsibilities with respect to the use of computerized systems
Recommended SOPs
Validation Center™ Copyright © 2021, ProPharma Group 137
HOMEWORK #2Which of the SOPs listed in Appendix
A does your company have? Any missing?
FDA Guidance
Validation Center™ Copyright © 2021, ProPharma Group 138
137
138
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
70
• Requirement – Any need or expectation for a system or for its software.
• Specification– A document that states requirements
Terminology
Validation Center™ Copyright © 2021, ProPharma Group 139
SPECIFICATION
• Requirement 1• Requirement 2• Requirement 3• Requirement 4• Requirement 5….• Requirement n
Terminology
Validation Center™ Copyright © 2021, ProPharma Group 140
VALIDATIONConfirmation by examination and provision of objective evidence that software specifications conform to user needs and intended uses, and that the particular
requirements implemented through software can be consistently fulfilled.
VALIDATIONConfirmation by examination and provision of objective evidence that software specifications conform to user needs and intended uses, and that the particular
requirements implemented through software can be consistently fulfilled.
HOMEWORK #3How does the FDA define “computer
system validation”?
URS Approval
FS Approval
Design Review
Code Walkthrough
Unit Testing
Trace Matrix
Validation Report
InstallationQualification
OperationalQualification
PerformanceQualification
SOPReview
Training Review
VERIFICATIONA conclusion that software is validated is highly dependent
upon comprehensive software testing, inspections, analyses, and other verification tasks performed at each
stage of the software development life cycle
HOMEWORK #4According to the
General Principles of Software Validation
guidance, a conclusion that software is
validated is highly dependent upon _____,
_____, _____, and other _____ performed
at each stage of the software development
life cycle
139
140
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
71
Terminology
Validation Center™ Copyright © 2021, ProPharma Group 141
VALIDATIONConfirmation by examination and provision of objective evidence that software specifications conform to user needs and intended uses, and that the particular
requirements implemented through software can be consistently fulfilled.
VALIDATIONConfirmation by examination and provision of objective evidence that software specifications conform to user needs and intended uses, and that the particular
requirements implemented through software can be consistently fulfilled.
URS Approval
FS Approval
Design Review
Code Walkthrough
Unit Testing
Trace Matrix
Validation Report
InstallationQualification
OperationalQualification
PerformanceQualification
SOPReview
Training Review
VERIFICATION TASKS
QUALIFICATIONFormal testing to
demonstrate that the software meets its
specified requirements.
• Most problems are traceable to errors made during the design and development process
• Typically, testing alone cannot fully verify that software is complete and correct
• Unlike hardware, software is not a physical entity and does not wear out– Software may improve with age as defects are discovered and removed
– However, software changes and improvements sometimes introduce new defects
• Software professionals are a highly mobile workforce, so accurate, thorough documentation is essential
Software is Different than Hardware
Validation Center™ Copyright © 2021, ProPharma Group 142
141
142
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
72
• Requirements: Requirements specifications provide the baseline for validation and verification. Software validation cannot be completed without requirements specifications
• Defect Prevention: In most cases software testing by itself is not sufficient to establish confidence that the software is fit for its intended use. Techniques also need to prevent software errors
• Software Development Life Cycle: Software validation takes place within an established software life cycle. This guidance does not recommend any particular life cycle models – only that one be selected and used for a software development project.
Key Principles of Software Validation
Validation Center™ Copyright © 2021, ProPharma Group 143
• Validation Procedures: Procedures establish “how” to conduct the software validation effort through a specific sequence of actions, activities, and tasks
• Validation Plans: The software validation plan defines “what” is to be accomplished through the software validation effort by specifying areas such as scope, approach, resources, schedules and the types and extent of activities, tasks, and work items.
• Validation Coverage: The selection of validation activities, tasks, and work items should be commensurate with the complexity of the software design and the safety risk associated with the use of the software for the specified intended use.
Key Principles of Software Validation
Validation Center™ Copyright © 2021, ProPharma Group 144
143
144
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
73
• Validation of Changes: Whenever software is changed, an analysis should be conducted to determine the impact of that change on the entire software system.
Based on this analysis, conduct an appropriate level of software regression testing to show that unchanged but vulnerable portions of the system have not been adversely affected.
Key Principles of Software Validation
Validation Center™ Copyright © 2021, ProPharma Group 145
• Examples: – Programmable logic controllers
– Statistical process control
– Supervisory control and data acquisition
– Robotics
– Human-machine interfaces
– Word processors
– Spreadsheets
– Databases
– Statistical packages
– Commercial databases and software applications
Automated Processes & Quality Systems
Validation Center™ Copyright © 2021, ProPharma Group 146
145
146
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
74
• Validation Effort & Evidence: – The level of validation effort should be commensurate with the risk posed by the
automated operation
– The requirements and risk analysis of the automated process help to define the scope of the evidence needed to show that the software is validated for its intended use
– The extent of validation evidence needed depends on the documented intended use of that software
Automated Processes & Quality Systems
Validation Center™ Copyright © 2021, ProPharma Group 147
For example, a company that chooses not to use all the vendor-supplied capabilities of the software only needs to validate
those functions that will be used and for which the company is dependent upon the software results
as part of production or the quality system
• Responsibility: The device manufacturer is responsible for ensuring that the product development methodologies used by the OTS software developer are appropriate and sufficient for the device manufacturer’s intended use
• Vendor Assessment: Depending upon the risk, consider auditing the vendor’s design and development methodologies.
The audit should demonstrate that the vendor’s procedures for and results of the verification and validation activities performed the OTS software are appropriate and sufficient.
Off the Shelf Software
Validation Center™ Copyright © 2021, ProPharma Group 148
HOMEWORK #5Who is ultimately responsible for
ensuring that software is validated for its intended use?
147
148
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
75
• Use of Vendor Documentation: If the vendor can provide information about their system requirements, software requirements, validation process, and the results of their validation, the information can be used as a beginning point for the end-user’s validation.
• Lack of Vendor Documentation: Where necessary validation information is not available from the vendor, the regulated company will need to perform sufficient system level “black box” testing to establish that the software meets their “user needs and intended uses.”
Off the Shelf Software
Validation Center™ Copyright © 2021, ProPharma Group 149
Requirements and Design:Begin with the End in Mind
Module 4
149
150
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
76
• Be able to describe, from a high level, the requirements and specification deliverables within the Computer System Validation process
Objectives
Validation Center™ Copyright © 2021, ProPharma Group 151
Introduction 21 CFR 11 and Annex 11
Framework, Deliverables,
& Plan
Requirements & Design
Validation Testing Evaluation
Classic Requirements Analogy
Validation Center™ Copyright © 2021, ProPharma Group 152
151
152
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
77
Basic Framework (GAMP 4 & 5)
Validation Center™ Copyright © 2021, ProPharma Group153
UserRequirementsSpecification
FunctionalSpecifications
DesignSpecifications
PerformanceQualificationTests (PQ)
OperationalQualificationTests (OQ)
InstallationQualification
Tests (IQ)
SystemBuild
Verifies
Verifies
Verifies
Planning ReportingVerifies
• Typical software and system requirements include:– All functions that the software system will perform.
Include data manipulations, calculations, data verification routines.
– How users will interact with the system. This could include screens and reports.
– All software system inputs and outputs
– What constitutes an error and how errors should be handled;
– All ranges, limits, defaults, and specific values that the software will accept
– Features needed to meet regulatoryrequirements
– All performance requirements that the software will meet
– All security and access requirements
– Any interfaces between systems
– Required response times
FDA Guidance on Requirements
Validation Center™ Copyright © 2021, ProPharma Group 154
− Record retention and destruction requirements.
− The intended operating environment for the software (if a constraint)
− All safety related requirements, specifications, features, or functions that will be implemented in software.
153
154
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
78
Levels of Specifications
Validation Center™ Copyright © 2021, ProPharma Group 155
Business
– Why the system is needed
– What benefits the system will provide or what problem the system will solve
– How the system will be used
Functional– What features and functions are needed in the
system in order to meet the business requirements
Technical– How the system must be built or
configured to provide the functionality needed
UserRequirementsSpecification
FunctionalSpecifications
DesignSpecifications
Documents with a Purpose
Validation Center™ Copyright © 2021, ProPharma Group 156
1. What is the style and language of each document?
2. Which document is critical for clear communication between the user community and the technical team?
3. Can you integrate the URS and FS documents? When is this appropriate?
4. For purchased systems, when should each document be authored and approved?
Business Audience Technical Audience
UserRequirementsSpecification
(URS)
FunctionalSpecification
(FS)
SystemDesign
Specification(SDS)
Contract
155
156
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
79
User Requirements vs. Functional Requirements
Validation Center™ Copyright © 2021, ProPharma Group 157
1.0 The system shall providea report of training statusfor each employee
User Requirement Functional Requirements
1.1 The user shall have the ability to run theTraining Status Report by1.1.1 Employee name1.1.2 Employee ID1.1.3 Department Number1.1.4 Company
1.2 The Training Status Report shall list1.2.1 Employee name1.2.2 Employee ID1.2.3 Employee Department Number1.2.4 Course Name1.2.5 Course ID etc.
1.3 Data on the Training Status Report shall besorted by department, employee ID, course ID
1.4 The Training Status Report shall be automatically printed on the requester’s default printer
Etc…
User Requirement
1.0 The system shall enable the document review, feedback,and approval process
2.0 The system shall providesecurity to data based onuser job title
3.0 The system shall alertappropriate personnel when a lab test fails
User Requirements vs. Functional Requirements
Validation Center™ Copyright © 2021, ProPharma Group 158
1.1 ?????
2.1 ?????
3.1 ?????
Functional Requirements
157
158
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
80
Guidance on Risk Management
Validation Center™ Copyright © 2021, ProPharma Group 159
Risk:A measure of the severity and probability of
of undesired effects.
Severity Common Definition
HighDirect impact on patient safety, product quality,or the integrity of associated data
MediumIndirect impact on patient safety, product quality,or the integrity of associated data
LowNo impact on patient safety, product quality, or the integrity of associated data
Probability Common Definition
High Complex implementation, e.g., custom designed and developed systems
Medium Less complex implementation, e.g., configured, off-the shelf applications
Low Simple implementation, e.g., non-configured off-the-shelf applications
Guidance on Risk Management
Validation Center™ Copyright © 2021, ProPharma Group 160
Risk Mitigation:Actions taken to reduce the severity or probability
of the undesired effect.
Validation Scope & Scale
• The selection of validation activities should be commensurate with the complexity of the software design and the risk associated with use of the software for its specific intended use.
• As the risk increases, additional validation activities should be added to cover the additional risk
• The amount of structural testing should be commensurate with the level of risk posed by the software.
• The amount of path coverage is normally established based on the risk or criticality of the software under test.
159
160
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
81
The System Design will include:
• How the features and functions identified in the FS will be provided;
• Software risk analysis;
• Development procedures and coding guidelines
• Hardware to be used;
• Parameters to be measured or recorded;
• Database Structure
• Network Structure
• Logical structure and logical processing steps
• Definitions of variables and description of where they are used;
• Error, alarm, and warning messages;
• Supporting software
• Communication links
• Security measures
FDA Guidance on Design Components
Validation Center™ Copyright © 2021, ProPharma Group 161
FDA Guidance on Design Process
Validation Center™ Copyright © 2021, ProPharma Group 162
• Most software development models will be iterative.
• This is likely to result in several versions of both the software requirement specification and the software design specification.
• All approved versions should be archivedand controlled in accordance with established configuration management procedures.
Change Request
FRS
Design BuildUnit Test
Quality Plan
Test Plans
Test Plans
Test Plans
(Designs)
Test Plans
Test Plans
Write Tests (OQ)
Test Plans
Test PlansRun OQs
QualitySummary
Report
Trace MatrixApplication
Provider
161
162
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
82
• For most packaged systems, the detailed design will consist of:– Customizations that you design and build
– Your configuration decisions• Required fields
• Field sizes
• User defined fields
• Security access
– Architecture, e.g. hardware
– References to vendor supplied documents• End User Documentation
• Technical Documentation.
System Design for Packages
Validation Center™ Copyright © 2021, ProPharma Group 163
Sufficient detail to set it up again the same way
• Source code should be evaluated to verify its compliance with specified coding guidelines.
– Such guidelines should include coding conventions regarding clarity, style, complexity management, and commenting
– Code comments should provide useful and descriptive information for a module, including:
• expected inputs and outputs,
• variables referenced,
• expected data types, and
• operations to be performed
Construction and Coding
Validation Center™ Copyright © 2021, ProPharma Group 164
163
164
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
83
1. If you are writing the User Requirements for a distribution system, who would be your primary interview target?a) Software vendor
b) In-house IT system analyst
c) Warehouse manager
2. Which of the following documents is the most technical?a) User Requirements Specification
b) Functional Specification
c) System Design Specification
3. True or False: A System Design Specification is not needed when implementing an off-the-shelf software package.
Exercise #4
Validation Center™ Copyright © 2021, ProPharma Group 165
Validation Testing: IQ, OQ, PQ
Module 5
165
166
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
84
• You will be able to discuss the principles of testing and the associated documentation that FDA expects
1. Understand the basics of validation testing
2. Explain the differences between IQ, OQ, PQ and how they apply to software.
3. Understand the key considerations for writing and executing tests.
Objectives
Validation Center™ Copyright © 2021, ProPharma Group 167
Introduction 21 CFR 11 and Annex 11
Framework, Deliverables,
& Plan
Requirements & Design
Validation Testing Evaluation
Basic Framework (GAMP 4 & 5)
Validation Center™ Copyright © 2021, ProPharma Group168
UserRequirementsSpecification
FunctionalSpecifications
DesignSpecifications
PerformanceQualificationTests (PQ)
OperationalQualificationTests (OQ)
InstallationQualification
Tests (IQ)
SystemBuild
Verifies
Verifies
Verifies
Planning ReportingVerifies
167
168
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
85
• Validation testing is only a part of the process of validating software, but it is…– Most labor-intensive activity and
– Produces the greatest amount of documentation
• The most common “objective evidence” are the results of the testing
Introduction
Validation Center™ Copyright © 2021, ProPharma Group 169
“Testing” is often mistaken for “Validation” itself (but it’s not synonymous)
Types of Testing
Validation Center™ Copyright © 2021, ProPharma Group 170
Unit Testing
Sub-program functionality and functionality not
visible at the system level
Integration Testing
The transfer of data and control across a program's internal
and external interfaces
System Testing
Considered the most important validation testing for a system
Tests that all specified functionality exists and the software product is
trustworthy
169
170
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
86
• A software testing process should be based on principles that foster effective examinations of a system.
• Some of these principles are:– The expected test outcome is predefined
– A good test case has a high probability of exposing an error• Examining only the usual case is insufficient
• There is steady-state testing (normal execution) and stress-testing (abnormal execution)
– There is independence from coding
– Test documentation permits independent confirmation of the pass/fail status of a test outcome during subsequent review
Principles of Testing
Validation Center™ Copyright © 2021, ProPharma Group 171
• Software testing has limitations that must be recognized and considered – Except for the simplest of programs, software cannot be exhaustively tested
• Generally, it is not feasible to test a software product with all possible inputs, nor is it possible to test all possible data processing paths that can occur during program execution
– There is no one type of testing or testing methodology that can ensure a particular software product has been thoroughly tested
Challenges of Validation Testing
Validation Center™ Copyright © 2021, ProPharma Group 172
171
172
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
87
• Software verification and validation are difficult because a developer cannot test forever. How much is enough?
• Quotes from the FDA Guidance on Software Validation:– The level of confidence, and therefore the level of software validation, verification,
and testing effort needed, will vary depending upon the safety risk (hazard) posed by the automated functions.
– Validation testing coverage should be based on the software’s complexity and safety risk.
– The amount of structural testing coverage should be commensurate with the level of risk posed by the software. Common structural coverage includes:
• Statement coverage
• Decision (branch) coverage
• Path coverage
Extent of Validation Testing
Validation Center™ Copyright © 2021, ProPharma Group 173
• The real effort of effective software testing lies in the definition of what is to be tested, rather than in the performance of the test
– What test data and test scenarios are most likely to uncover a software defect?
– What test data and test scenarios are similar to expected production use conditions?
– What test data and test scenarios simulate extreme production use?
• Need both technical and business expertise to define thorough tests
• Can use documented Test Plans. Especially useful when…– Testing complex logic
– Using inexperienced or contract resources to write tests
Validation Test Design
Validation Center™ Copyright © 2021, ProPharma Group 174
173
174
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
88
Validation and Verification
Validation Center™ Copyright © 2021, ProPharma Group 175
The conclusion that software is validated is based on the outcome of all of the verification activities
VALIDATION
VERIFICATION…consistency, completeness,
and correctness of the software
and its supporting
documentation, ….
URS Approval
FS Approval
Design Review
Code Walkthrough
Unit Testing
Trace Matrix
Validation Report
PerformanceQualification
OperationalQualification
InstallationQualification
SOPReview
Training Review
QUALIFICATIONFormal testing to demonstrate that
the software meets its specified
requirements.
Basic Validation Framework
Validation Center™ Copyright © 2021, ProPharma Group 176
UserRequirementsSpecification
FunctionalSpecifications
DesignSpecifications
PerformanceQualification
Tests (PQ)
OperationalQualificationTests (OQ)
InstallationQualification
Tests (IQ)
SystemBuild
Verifies
Verifies
Verifies
Planning ReportingVerifies
Verifies Installation and Set Up
Verifies thatRequired FeaturesFree from Defects
Verifies that system isSuitable for Business Use
175
176
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
89
• Installation Qualification (IQ) is a documented process that ensures that the system is installed properly. In can include:
– Documentation of the installed versions of all hardware, software, and peripheral devices
– Steps for set up and configuration of • Hardware
• Support software, e.g., server software, databases, operating systems, interface software
• Application software
• Peripheral devices, e.g., scanners, sensors, printers, or other data collecting or recording components
– Verification that all of the system components have been installed and set up according to the Design
• IQ must be performed for the Production environment
• IQ is often also performed for the Validation Testing environment
Installation Qualification (IQ)
Validation Center™ Copyright © 2021, ProPharma Group 177
• The IQ can be written as a single protocol or be organized a separate protocols. For example,
Installation Qualification (IQ)
Validation Center™ Copyright © 2021, ProPharma Group 178
IQ for System
Installation
IQ for System
Configuration
IQ for System
Hardware
IQ for System
Software
IQ for Network
IQ for Server
IQ for Operating System
IQ for Application Software
IQ for Printers
IQ for Printers
IQ for Printers
IQ for Printers
IQ for System
Peripheral Devices
© 2019 Praxis Life Sciences
177
178
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
90
• Operational Qualification (OQ) is a documented process that ensures that the system operates properly.
• The OQ tests the features defined in the Functional and Design Specifications.
• OQ Testing can include:– Testing each system feature
– Testing configurations (e.g., security groups, drop down menus) and calculations
– Navigating to all parts of the system to show that all of the pieces work
– Testing input and output peripherals (e.g., printers, scanners, data entry devices) to ensure that they work with the entire system
– Testing system performance under simulated use conditions
Operational Qualification (OQ)
Validation Center™ Copyright © 2021, ProPharma Group 179© 2019 Praxis Life Sciences
• Data for Operational Qualification (OQ) testing is created both before and during the testing
• The OQ can be performed in either:– A designated Validation environment [TYPICAL]
– A Production environment that is not yet in use • NOTE: When the OQ is run in the Production Environment, all test data must be removed to
not contaminate production data.
Operational Qualification (OQ)
Validation Center™ Copyright © 2021, ProPharma Group 180© 2019 Praxis Life Sciences
179
180
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
91
• Performance Qualification (PQ) is a documented process that ensures that the system is suitable for intended use.
• PQ testing verifies that requirements documented in the User Requirements Specifications.
• PQ testing can include:– Verification that the system has the features needed to support automation of the
business operations
– Testing following pre-defined Use Cases
– Testing following processes in SOPs
– Testing vs. requirements in predicate rules
– Testing with a copy of “live” data
Performance Qualification (PQ)
Validation Center™ Copyright © 2021, ProPharma Group 181© 2019 Praxis Life Sciences
• Data for Performance Qualification (PQ) testing is created both before and during the testing
• The PQ can be performed in either:– A designated Validation environment [TYPICAL]
– A Production environment• NOTE: When the PQ is run in the Production Environment, all test data must be removed to
not contaminate production data.
Performance Qualification (PQ)
Validation Center™ Copyright © 2021, ProPharma Group 182© 2019 Praxis Life Sciences
181
182
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
92
When to Combine the OQ & PQ
Validation Center™ 183© 2019 Praxis Life Sciences
When can you combine the OQ and PQ vs. writing separate document?
Separate
• Large systems
• Complex custom programs
• Purchased software, especially when
• Vendor provides OQ
• Purchasing company creates PQ
Together
• Small projects
• Simple program logic
Copyright © 2021, ProPharma Group
OQ and PQ Test Documentation Hierarchy
Validation Center™ Copyright © 2021, ProPharma Group 184
Validation Plan
Test Protocol 1 Test Protocol 2
Test Case 1
Step 1Step 2Step 3, etc…
Test Case 2, etc…
etc…
183
184
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
93
OQ and PQ Test Documentation Hierarchy
Validation Center™ Copyright © 2021, ProPharma Group 185
Lab System Test Plan
Incoming Sample Receipt
Lab Analyst Assignment
Verify Analyst Availability
Step 1,Step 2, Step 3, etc…
Verify Analyst Training
Assign Analyst to Tests
Notify Analyst via E-Mail
Test Result Entry
Test Reporting
Test Cases
Protocols
Example Test Case Format
Validation Center™ Copyright © 2021, ProPharma Group 186
Test Description and Objective:
Prerequisites:
Data Set Up:
Test Case: _____
Test Steps:
Reviewed by: _________________________
Step Action Expected Result Actual ResultConclusion (Pass/Fail)
Initials & Date
Comment
185
186
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
94
Step Action Expected Result Actual ResultConclusion (Pass/Fail)
Initials & Date
Comment
Test Description and Objective
Validation Center™ Copyright © 2021, ProPharma Group 187
Test Description and Objective:
Prerequisites:
Data Set Up:
Test Case: _____
Test Steps:
Reviewed by: _________________________
Briefly describe the test protocol (or case) and it’sobjectives.
E.g., “The purpose of this test case is to verify the ABC System’s functionality for managing inventory
levels”
Step Action Expected Result Actual ResultConclusion (Pass/Fail)
Initials & Date
Comment
Test Prerequisites
Validation Center™ Copyright © 2021, ProPharma Group 188
Test Description and Objective:
Prerequisites:
Data Set Up:
Test Case: _____
Test Steps:
Reviewed by: _________________________
Identify any conditions or activities that must be performed for the test to run correctly.
For Example:-Tester must be logged into the system with
“Supervisor” level access
- Tester must be using a PC with MS Office version 7.0 or higher
- Tester must be set up to print labels to bar code printer BCP-27-NC
187
188
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
95
Step Action Expected Result Actual ResultConclusion (Pass/Fail)
Initials & Date
Comment
Test Data Setup
Validation Center™ Copyright © 2021, ProPharma Group 189
Test Description and Objective:
Prerequisites:
Data Set Up:
Test Case: _____
Test Steps:
Reviewed by: _________________________
Provide instructions for locating or setting up the data needed for the test to run correctly.
For Example:- Select a Product ID with at least 100 pounds of
inventory in Warehouse 7. Record the Product ID selected: ____________
OR
- Set up new Product ID, X-42-001 with thefollowing attributes …..
- Add 100 pounds of inventory to Product ID X-42-001
Step Action Expected Result Actual ResultConclusion (Pass/Fail)
Initials & Date
Comment
Test Numbering
Validation Center™ Copyright © 2021, ProPharma Group 190
Test Description and Objective:
Prerequisites:
Data Set Up:
Test Case: _____
Test Steps:
Reviewed by: _________________________
Give each Protocol, Test Case, and Test Step number.
This helps with other documentation, such as Trace Matrices, Issue Reports, and Test Summaries
Give each Protocol, Test Case, and Test Step number.
This helps make references easier in other documentation, such as Trace Matrices, Issue
Reports, and Test Summaries
189
190
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
96
Step Action Expected Result Actual ResultConclusion (Pass/Fail)
Initials & Date
Comment
Test Instructions
Validation Center™ Copyright © 2021, ProPharma Group 191
Test Description and Objective:
Prerequisites:
Data Set Up:
Test Case: _____
Test Steps:
Reviewed by: _________________________
Instruct the Tester on what to do to test the requirements
• Cover all of the requirements and testing techniques that you identified, per your Test Plan
• Provide sufficient details (but not too much) for the experience level of the tester
– Contract testers will need more detail than regular system users
– Off site testers might need more detail than on site testers
– Extremely detailed tests take longer to write
– Extra detail can cause problems if the system doesn’t exactly match what is written
Test “Action” Instructions
Validation Center™ Copyright © 2021, ProPharma Group 192
191
192
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
97
Type of Test “Action” Instructions
Validation Center™ Copyright © 2021, ProPharma Group193
Set-up Steps Prepare the system’s data or configuration
for testing
For Example• Set access levels
• Create specific data
• Turn configurationoptions on/off
• Look up currentvalues
• Run reports toreference duringtesting
Test Steps Challenge
requirements and provide evidence of
functionality and conformance
For Example
• Check an errormessage
• Create a report
• Calculate a result
• Verify navigation
Navigation Steps
Move around the system while
performing the Test Steps – when
navigation is not being tested
For Example• Go to the report
menu
• Return to the dataentry screen
Step Action Expected Result Actual ResultConclusion (Pass/Fail)
Initials & Date
Comment
Expected and Actual Results
Validation Center™ Copyright © 2021, ProPharma Group 194
Test Description and Objective:
Prerequisites:
Data Set Up:
Test Case: _____
Test Steps:
Reviewed by: _________________________
Predefine the outcome of each Action taken by the Tester
Provide a way to record the actual outcome and the Tester’s pass/fail decision
193
194
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
98
• Actual results– Tester writes in empty cells in the test case
– Simplest to author
– Most labor intensive to execute
– Most prone to tester errors in documentation
Results
Validation Center™ Copyright © 2021, ProPharma Group 195
Action Expected Result Actual ResultConclusion (Pass/Fail)
On the Incoming Inventory Screen, Receive 100.0 kilograms of Product XY-1427-01 from Vendor AJ-1234-Ox
<Print Result>
The Incoming Inventory Confirmation Screen shows 100.0 kilograms of Product XY-1427-01 from Vendor AJ-1234-Ox. Receipt date is today’s date.
• Fill in the blank– Tester fills in a specific value or observation (e.g. record the number of names
displayed)
– Minimal extra effort for the author (a lot of cut and paste)
– Reduces test execution work
Results
Validation Center™ Copyright © 2021, ProPharma Group 196
Action Expected Result Actual ResultConclusion (Pass/Fail)
On the Incoming Inventory Screen, Receive 100.0 kilograms of Product XY-1427-01 from Vendor AJ-1234-Ox
<Print Result>
The Incoming Inventory Confirmation Screen shows 100.0 kilograms of Product XY-1427-01 from Vendor AJ-1234-Ox. Receipt date is today’s date.
The Incoming Inventory Confirmation Screen shows ____ kilograms of Product XY-1427-01 from Vendor AJ-1234-Ox. Receipt date is _______.
195
196
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
99
• Checkbox– Tester checks the box of the result (e.g. the following field appears….)
– Minimal extra effort for the author (a lot of cut and paste)
– Reduces test execution work
Results
Validation Center™ Copyright © 2021, ProPharma Group 197
Action Expected ResultActual Result (check box)
Conclusion (Pass/Fail)
On the Incoming Inventory Screen, Receive 100.0 kilograms of Product XY-1427-01 from Vendor AJ-1234-Ox
<Print Result>
The Incoming Inventory Confirmation Screen shows 100.0 kilograms of Product XY-1427-01 from Vendor AJ-1234-Ox. Receipt date is today’s date.
The Incoming Inventory Confirmation Screen shows 100.0 kilograms of Product XY-1427-01 from Vendor AJ-1234-Ox.
Receipt date is today’s date.
Did not obtain expected result
• Checkbox - Variation– Combine “Actual Result” and “Conclusion (Pass/Fail)” Steps
– Least burdensome for both author and tester
– Support with screen prints for critical requirements
– Train Testers to record details of failures in the “Comments” column
Results
Validation Center™ Copyright © 2021, ProPharma Group 198
Action Expected ResultActual Result Matches
Expected Result?(check box)
Comments
On the Incoming Inventory Screen, Receive 100.0 kilograms of Product XY-1427-01 from Vendor AJ-1234-Ox
<Print Result>
The Incoming Inventory Confirmation Screen shows 100.0 kilograms of Product XY-1427-01 from Vendor AJ-1234-Ox. Receipt date is today’s date.
Yes – Pass
No – Fail
197
198
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
100
• An essential element of a software test case is the expected result– It is the key detail that permits object evaluation of the actual test result
– Necessary testing information is obtained from the corresponding, predefined definition or specification
Objective Evidence
Validation Center™ Copyright © 2021, ProPharma Group 199
Test documentation should allow for objective decision making subsequent to running the test
What’s your
evidence?
• Screen capture– Best method to allow objective decision making subsequent to running the test
– Limit to steps that verify requirements
– Can be challenging for the Tester• Labeling screen captures takes time
• Missed screen captures cause rework
• Reports and database queries– Captures both the format and data content
– IQ any utility used to run ad hoc queries; verify query logic
• Witnessed result– A second person observes the test execution
– OK for non-critical applications
– Option when there’s no other means to generate objective evidence
Objective Evidence
Validation Center™ Copyright © 2021, ProPharma Group 200
199
200
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
101
Step Action Expected Result Actual ResultConclusion (Pass/Fail)
Initials & Date
Comment
Tester & Verifier Initials, Date, Comments
Validation Center™ Copyright © 2021, ProPharma Group 201
Test Description and Objective:
Prerequisites:
Data Set Up:
Test Case: _____
Test Steps:
Reviewed by: _________________________
Provide a means to document who
performed the test and when it was
performed
Provide a means to document who performed the test and when it was performed
Also provide a means to document who reviewed the executed test and confirmed the tester’s
actual results and pass/fail conclusion
(optional) Provide space for any
comments by the Tester
• A Test Failure occurs any time a test step’s Actual Result does not exactly match the Expected Result
• Examples of Test Failures:– Screen shows 101.0 kilograms
– Screen shows 100 kilograms
– Screen shows 100,000 grams
– Screen shows Vendor AJ-2345-Ox
– Receipt date is tomorrow
Test Failures
Validation Center™ Copyright © 2021, ProPharma Group 202
Action Expected Result
On the Incoming Inventory Screen, Receive 100.0 kilograms of Product XY-1427-01 from Vendor AJ-1234-Ox
The Incoming Inventory Confirmation Screen shows 100.0 kilograms of Product XY-1427-01 from Vendor AJ-1234-Ox. Receipt date is today’s date.
201
202
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
102
Reasons for Failed Tests
Validation Center™ Copyright © 2021, ProPharma Group203
Test ErrorFailedTests
Tester E
rror
Functional Error
Test Failure Documentation
Validation Center™ Copyright © 2021, ProPharma Group204
System Name: ________Software Version Number: ________
Validation Protocol ID: ________Test Case: ________Test Step Number: ________Date of Incident: ________
Incident Cause: ____________________________________________________________________________________
Correction Required: ____________________________________________________________________________________
Incident Description: ____________________________________________________________________________________
Correct Operation: ____________________________________________________________________________________
Identify Test Failure
Describe what the software did, and
what it should have done
Action(s) Required to Verify Correction: _____________________________________________________________________________
Describe what caused the failure,
and what it will take to fix it
Describe how you will prove that the problem has been
fixed
203
204
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
103
• Testing may uncover defects that cannot be fixed prior to production use.
• There must be a justification of why the system can be used with the defect. Possible options are:
– The defective feature of the application is rendered off-limits
– The defect is so minor that is has negligible effect on system quality
– Users are trained in a workaround process to avoid the defect
Unresolved Defects
Validation Center™ Copyright © 2021, ProPharma Group 205
Trace Matrix
Validation Center™ Copyright © 2021, ProPharma Group 206
UserRequirementsSpecification
FunctionalSpecifications
DesignSpecifications
PerformanceQualification
Tests (PQ)
OperationalQualificationTests (OQ)
InstallationQualification
Tests (IQ)
SystemBuild
Verifies
Verifies
Verifies
Planning ReportingVerifies
205
206
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
104
• The documentation from testing includes:– Trace matrix showing where each requirements was verified through testing
– The completed set of test protocols
– Objective evidence: reports, screen prints, and other system outputs
– All Validation Incident Reports
– A testing summary (aka Test Report) of how the testing was conducted, the disposition of errors encountered, and the testing results*
Validation Testing Documentation
Validation Center™ Copyright © 2021, ProPharma Group 207
* For small projects, the testing summary can be included in the Validation Report
Basic Framework (GAMP 4 & 5)
Validation Center™ Copyright © 2021, ProPharma Group208
UserRequirementsSpecification
FunctionalSpecifications
DesignSpecifications
PerformanceQualificationTests (PQ)
OperationalQualificationTests (OQ)
InstallationQualification
Tests (IQ)
SystemBuild
Verifies
Verifies
Verifies
From ISPE
Planning ReportingVerifies
207
208
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
105
• The results of validation effort are documented in the Validation Report.
• The Validation Report describes:1. Summary of testing results, including issues and corrections
2. A list of each deliverable and where it can be found
3. Any deviations from the Validation Plan – with justification
4. Confirmation that all activities described in the Validation Plan have been completed
5. Confirmation of the Acceptance Criteria from the Validation Plan
6. Authorization to move the system into production
Documenting the Results
Validation Center™ Copyright © 2021, ProPharma Group 209
ValidationReport
1. What is the purpose of validation testing?
2. If you are writing a PQ, you would want to make sure that you verified all ofthe requirements of which specification?a) User Requirements Specification
b) Functional Specification
c) System Design Specification
3. Why do validation testing protocols typically require that the tester capture screen prints?
Exercise #5
Validation Center™ Copyright © 2021, ProPharma Group 210
209
210
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
106
Final Exam
80% or better
Complete the Final Exam
Return (email) completed Exam to [email protected]
Return to class in 30 minutes and we will review the answers
Final Exam
Validation Center™ Copyright © 2021, ProPharma Group 212
Introduction 21 CFR 11 and Annex 11
Framework, Deliverables,
& Plan
Requirements & Design
Validation Testing Evaluation
211
212
Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from ProPharma Group is prohibited.
Copyright © 2021 ProPharma Group. All rights reserved.
ProPharma Group | propharmagroup.com10 Parkway North, Suite 310 Deerfield IL 60015 | +1 (847) 295-7160
Validation Center™Validationcenter.com
107
Thank You!
Follow us!
Rodrigo Perez(+1) 847-295-7160 [email protected]
Validation Center™ Copyright © 2021, ProPharma Group 213
213